Orexigen, positive results in two Phase I clinical trials of naltrexone, key component of the Company's lead product candidate for obesity, Contrave

Sep 25, 2007 - Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced positive results in two Phase I clinical trials of its proprietary sustained release (SR) formulation of naltrexone. Orexigen has developed this proprietary SR formulation of naltrexone with the objective of improving tolerability by modifying the pharmacokinetics of immediate release (IR) naltrexone. Naltrexone is a key component of the Company's lead product candidate for obesity, Contrave, which is currently being studied in Phase III clinical trials... Orexigen's Press Release -